References
- Berry, S. M., Carlin, B. P., Lee, J. J. and Muller, P. (2010). Bayesian Adaptive Methods for Clinical Trials. Boca Raton, FL: Chapman and Hall/CRC Press.
- Dignam, J. J., Bryant, J. and Wieand, H.S. (2006). Early Stopping of Cancer Clinical Trials. Chapter 14. In J. Ankerst, and D. P. Ankerst (Eds), Handbook of Statistics in Clinical Oncology, 2nd ed., pp. 227–246. Boca Raton, FL: Chapman Hall/CRC Press.
- FDA Guidance for Industry (2010). Adaptive Design Clinical Trials for Drugs and Biologics. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration.
- Gasparini, M., Di Scala, L., Bretz, F., and Racine-Poon, A. (2013). Predictive probability of success in clinical drug development. Epidemiology Biostatistics and Public Health 10(1):e8760-1–e8760-14.
- Gelbert, R. D., Goldhirsch, A., Cole, B. F., Wieand, H. S., Schroeder, G., and Krook, J. E. (1996). A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. Journal of National Cancer Institute 88(15):1039–1045.
- Johns, D. and Anderson, J. (1999). Use of predictive probabilities in phase II and phase III clinical trials. Journal of Biopharmaceutical Statistics 9(1):67–79.
- Lan, K. K., DeMets, D. L. (1983). Discrete sequential boundaries for clinical trials. Biometrika 70:659–63
- Spiegelhalter, D. J., Freedman, L. S. and Blackburn, P. R. (1986). Monitoring clinical trials:Conditional or predictive power. Controlled Clinical Trials 7:8–17.
- Tang, Z. and Dey, J. (2013). Bayesian PPOS design for pilot trial development. JSM, abstract #: 307881.
- Tang, Z. (2015). Optimal futility interim design: a predictive probability of success approach with time to event end point. Journal of Biopharmaceutical Statistics 25(6):1312–1319.
- Wang, Y., Fu, H., Kulkarni, P. and Kaiser, C. (2013). Evaluating and utilizing probability of study success in clinical development. Clinical Trials 10:407–413.